FORT COLLINS, Colo., May 25 /PRNewswire-FirstCall/ -- Atrix Laboratories, Inc. announced today its $33,359 contribution to the Larimer County Food Bank during the Corporate Food Drive Challenge.
"We are very pleased that we are able to make this contribution to the food bank," said Atrix Chairman and Chief Executive Officer David R. Bethune. "I am proud of our effort and 100 percent employee participation for such a worthy cause."
There were a total of 23 participating companies in this year's corporate challenge to combat hunger in Larimer County and a total of $73,300 was raised for the Food Bank. For the second year in a row, Atrix was awarded two trophies for its contribution: Corporate Champion for Outstanding Contribution and Corporate Champion for Largest Financial Contribution.
Over the course of two weeks, Atrix employees held car washes, silent auctions, bake sales and a variety of other activities to raise money for the food bank. They also collected canned goods as part of the total donation.
Atrix Laboratories, Inc. is an emerging specialty pharmaceutical company focused on advanced drug delivery. With unique sustained release and topical technologies, Atrix is currently developing a diverse portfolio of proprietary products, including oncology, pain management, and dermatology products. The company also partners with large pharmaceutical and biotechnology companies to apply its proprietary technologies to new chemical entities or to extend the patent life of existing products. Additional information is available on the Atrix Laboratories, Inc. website at http://www.atrixlabs.com/.
Statements contained in this press release, which are not historical facts, are forward-looking statements, as the term is defined in the Private Securities Litigation Reform Act of 1995.
The company is subject to certain risk factors that may cause actual results to differ materially from anticipated results. Those risks include, but are not limited to, risks associated with product demand, pricing, market acceptance, changing economic conditions, risks in product and technology development and competition from other products and treatments. For additional information about risk factors, please see the reports filed by the company with the SEC, including the company's Annual Report on Form 10-K for the year ended December 31, 2002 and the company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2003. All forward-looking statements in this press release are made as of the date hereof, based on information available to the company as of the date hereof, and the company assumes no obligation to update or revise any of its forward-looking statements even if experience or future changes show that the indicated results or events will not be realized.
Atrix Laboratories, Inc.
CONTACT: Company Contact: Danette R.M. Meyer, Ph.D.(Dmeyer@atrixlabs.com), Director of Investor Relations, Atrix Laboratories,Inc., +1-970-482-5868